Featured News

2024 International Metabolic Conference for Fatty Acid Oxidation Disorders

International Metabolic Conference Flyer, July 26-28, 2024, with QR code to registe.r
2024 International Metabolic Conference for FAODs flyer

We would like to share that MitoAction, in conjunction with INFORM, is hosting their 5th Annual International Metabolic Conference for Fatty Acid Oxidation Disorders (FAODs) in Detroit, MI on July 26-28, 2024! This will be a great space for patients, families, and caregivers to learn more about disease management, current clinical trials, and living day to day with an FAOD, while networking with other families and professionals who specialize in metabolic disorders. We hope you will consider this wonderful opportunity!

Visit MitoAction.org to learn more and register.

Fall/Winter 2023 Research Newsletter is out!

The Fall/Winter 2023 edition of our research newsletter is now available. In the newsletter we share news of our recent publication in the journal Communications Biology and the findings of our retroactive medical record review of cardiomyopathy and sudden cardiac events in adolescent and young adult LCHADD patients.

You can download a copy of the newsletter from our Newsletter page. If you would like to be added to our newsletter email subscribers list, please fill out our Contact Form.

MitoAction.org Expert Series Presentation

On November 1st, Dr. Gillingham presented an update on the current results of our LCHADD retinopathy natural history study of 40 patients during the monthly MitoAction Expert Series. You can watch a recording of the presentation on the MitoAction website.

If you'd like to see recordings of previous presentations by Dr. Gillingham, visit our Publications & Presentations page.

New publication!

Screenshot of Communications Biology journal article title and authors.

We have a new article published in the journal, Communications Biology. The title of the article is “A G1528C Hadha knock-in mouse model recapitulates aspects of human clinical phenotypes for long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency”. The article details the development of our novel LCHADD mouse model which will allow us to further study the various complications of LCHADD and to test new therapies.

The article is available to read online.